A Randomised, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of PN-235 in Healthy Volunteers
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Icotrokinra (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Protagonist Therapeutics
Most Recent Events
- 03 Nov 2021 According to a Protagonist Therapeutics media release, the company has been completed this phase 1 study.
- 03 Nov 2021 Status changed from recruiting to completed, according to a Protagonist Therapeutics media release.
- 04 May 2021 According to a Protagonist Therapeutics media release, the company expects to complete this study in the second half of 2021.